Search
for
Sort by
Research 30 of 40
- Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)
- Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
- Abiraterone and spironolactone in prostate cancer: a combination to avoid
- New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
- BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
- The impact of exercise on tolerability of systemic treatment in metastatic colorectal cancer: A literature review
- Therapeutic Strategies to Target the Androgen Receptor
- Management of teenagers with polycystic ovarian syndrome
- Testosterone target therapy: focus on immune response, controversies and clinical implications in patients with COVID-19 infection
- Repurposing steroidogenesis inhibitors for the therapy of neuropsychiatric disorders: Promises and caveats
- Hétérogénéité tumorale du cancer de la prostate et infection par le SARS-CoV2 : une relation complexe impliquant les vésicules extracellulaires et le récepteur des androgènes
- Computational Evaluation of Dibenzo Compounds as Potential Dual Inhibitors of Androgen Receptor and 5α-Reductase
- Baiting Proteins with C<sub>60</sub>
- Infantile vitiligo and alopecia in immunodysregulation polyendocrinopathy enteropathy X‐linked syndrome
- Update on Hormonal Therapy in Hidradenitis Suppurativa
- CD34 and BerEP4 Are Helpful to Distinguish Basaloid Tricholemmoma From Basal Cell Carcinoma
- PROTACs in 2025: from the laboratory concept to clinical breakthrough
- Identifying effective immune biomarkers in alopecia areata diagnosis based on machine learning methods
- Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
- PROTACs: A novel strategy for cancer drug discovery and development
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis
- Antiandrogens as Therapies for COVID-19: A Systematic Review
- Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
- Advances and Perspectives on Bioelectronic and Atomic Nanogenerators for Anticancer Therapy
- Evolving CRBN ligands enhance the drug-like properties of protein degraders
- Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape within Targeted Protein Degradation
- Editorial: Androgen-dependent diseases and their treatment
- Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
- <i>Saccharomyces cerevisiae</i> BLYAS, a New Bioluminescent Bioreporter for Detection of Androgenic Compounds